The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The facility will manufacture its Herceptin biosimilar, Tuznue
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Subscribe To Our Newsletter & Stay Updated
